Poster preview
ePoster
BLOOD GLUTAMINE IS CRITICAL FOR NEUROTRANSMITTER SYNTHESIS, ENERGY HOMEOSTASIS, AND SYNAPTOGENESIS IN THE DEVELOPING BRAIN
Inna Radzishevskyand 4 co-authors
Technion
FENS Forum 2026 (2026)
Barcelona, Spain
Board PS05-09AM-341
Presentation
Date TBA
Board: PS05-09AM-341
Event Information
Poster Board
PS05-09AM-341
Poster
View posterAbstract
Biallelic mutations in SLC38A3 (SN1) lead to postnatal progressive microcephaly, epilepsy, and intellectual disability. However, the underlying pathophysiology remains unknown. Here, we identified Slc38a3 (SN1) expressed at the vascular endothelium as a critical glutamine transporter that mediates blood-to-brain influx of glutamine through the blood-brain barrier (BBB).
Endothelial selective deletion of Slc38a3 (Slc38a3-cKO) lowered the influx of glutamine across the BBB and decreased brain glutamine levels in mouse pups. This was associated with lower transfer of glutamine carbons to glutamate and GABA, suggesting impairment of the glutamine-glutamate/GABA metabolic cycle. Like individuals with mutations in SLC38A3, Slc38a3-cKO pups developed postnatal progressive microcephaly as well as behavioural impairments and morphological alterations in synapses. Approximately 30% of Slc38a3-cKO pups fail to thrive, exhibiting motor dysfunction and preweaning lethality. Glutamine deficiency in the Slc38a3-cKO hippocampus was associated with a slower TCA cycle and a seemingly adaptive increase in glycolysis rate. Glutamine supplementation replenished brain glutamine, prevented microcephaly, and normalized motor behavior in Slc38a3-cKO pups, indicating that brain glutamine deficiency is the primary cause of the phenotype.
In contrast to the dogma that all glutamine is produced locally in the brain, our data show that Slc38a3 provides blood-derived glutamine for neurotransmitter synthesis, energy metabolism, and synaptogenesis. Our findings suggest that SLC38A3 mutations cause a glutamine-related BBB aminoacidopathy and developmental disorder, which may be amenable to glutamine supplementation therapy.
Endothelial selective deletion of Slc38a3 (Slc38a3-cKO) lowered the influx of glutamine across the BBB and decreased brain glutamine levels in mouse pups. This was associated with lower transfer of glutamine carbons to glutamate and GABA, suggesting impairment of the glutamine-glutamate/GABA metabolic cycle. Like individuals with mutations in SLC38A3, Slc38a3-cKO pups developed postnatal progressive microcephaly as well as behavioural impairments and morphological alterations in synapses. Approximately 30% of Slc38a3-cKO pups fail to thrive, exhibiting motor dysfunction and preweaning lethality. Glutamine deficiency in the Slc38a3-cKO hippocampus was associated with a slower TCA cycle and a seemingly adaptive increase in glycolysis rate. Glutamine supplementation replenished brain glutamine, prevented microcephaly, and normalized motor behavior in Slc38a3-cKO pups, indicating that brain glutamine deficiency is the primary cause of the phenotype.
In contrast to the dogma that all glutamine is produced locally in the brain, our data show that Slc38a3 provides blood-derived glutamine for neurotransmitter synthesis, energy metabolism, and synaptogenesis. Our findings suggest that SLC38A3 mutations cause a glutamine-related BBB aminoacidopathy and developmental disorder, which may be amenable to glutamine supplementation therapy.
Recommended posters
CHRONIC GLUTAMATERGIC MODULATION RESTORES CORTICAL CIRCUIT FUNCTION AND AMELIORATES SEIZURE, MOTOR, AND BEHAVIORAL PHENOTYPES IN STXBP1 ENCEPHALOPATHY
Niklas Jeske, Victor Larsen, Altair Brito dos Santos, Joakim Palmqvist, Silas Dalum Larsen, Anna Christine Lera Nielsen, Carlos Daniel Gomez, Elisa Pfannenmueller, Walid Outtaleb, Josefine Hededal, Hilde Gunnink, Nikolaj Winther Hansen, Anne Marie Nordvig Petersen, Rikke Steensbjerg Møller, Jakob Balslev Sørensen, Robertas Guzulaitis, Carmelo Bellardita, Jean-Francois Perrier
THE PATHOGENIC KCC2 R857G VARIANT INDUCES ALTERED CORTICAL DEVELOPMENT AND IMPAIRED GABA SIGNALING IN A NOVEL EIMFS MOUSE MODEL
Esther Bliard, Pauline Weinzettl, Driss El Ouardi, Massimo Mantegazza, Alessandra Pierani, Barbara Bardoni, Jean Christophe Poncer
SLC45A1–HTR2A AXIS DRIVES FEMALE-BIASED CORTICAL E/I IMBALANCE UNDERLYING NEURODEVELOPMENTAL DISORDER PHENOTYPES
Hyunjin Kim, Hyowon Lee, Yeon Ha Ju, Seungha Kim, Sharon Jiyoon Jung, Seungjae Hyeon, Hae Nim Lee, Hoon Ryu, Jihye Seong, Gayeong Lim, Bum-Ho Bin, Min-Ho Nam
RESCUING BLOOD–BRAIN BARRIER GLUCOSE TRANSPORT IN GLUT1-DS USING ENGINEERED EPCS UNDER DYNAMIC FLOW CONDITIONS: A STEP TOWARD CELL-BASED THERAPY
Camilla D'Angelo, Gaia Lesca, Silvia Fallarini, Vasco Meneghini, Paolo Monti, Silvia Garavaglia
CEREBELLAR AND HIPPOCAMPAL AMMONIA ELEVATION ACROSS LIVER DISEASE STAGES: IMPLICATION OF GLUTAMINASE
Gergana Mincheva, Tiziano Balzano, Amparo Urios, Marta Llansola, Vicente Felipo, Carmina Montoliu
GLUD1 MUTATIONS ASSOCIATED WITH INTELLECTUAL DISABILITY ALTER SYNAPTIC CLUSTERING AND RECEPTOR MEMBRANE DYNAMICS, AS WELL AS GROUP I MGLU RECEPTOR–DEPENDENT REGULATION
Anouk Kletz, Fanette Seité, Giulia Fratti, Marion Russeau, Tania Lima Antunes, Sabine Levi, Ludovic Tricoire